OncoZenge AB Company Description

OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden.

It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of pain in the oral cavity.

The company was incorporated in 2020 and is headquartered in Bromma, Sweden.

OncoZenge AB (publ)

Country	Sweden
Founded	2020
Industry	Pharmaceutical Preparations
Employees	1
CEO	Stian Kildal

Contact Details

Address: GustavslundsvAegen 34 Bromma, 167 51 Sweden
Phone	46 8 31 14 20
Website	oncozenge.com

Stock Details

Ticker Symbol	8LY
Exchange	Frankfurt Stock Exchange
Fiscal Year	January - December
Reporting Currency	SEK
SIC Code	2834

Key Executives

Name	Position
Stian Kildal	Chief Executive Officer
Michael Owens	Chief Financial Officer